Welcome to LookChem.com Sign In|Join Free

CAS

  • or

3562-63-8

Post Buying Request

3562-63-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

3562-63-8 Usage

Chemical Properties

White Solid

Uses

Megestrol is an orally active progestogen. Megestrol is used in combinations as oral contraceptive and as antineoplastic agent.

Definition

ChEBI: A 3-oxo Delta4-steroid that is pregna-4,6-diene-3,20-dione substituted by a hydroxy group at position 17.

Indications

As a representitive of the compounds of the class of progestins, this drug is used for various forms of cancer, in particular cancer of the breast, kidneys, and others.

Brand name

Megace (Bristol-Myers Squibb); Megace (Par);Citestrol;Co-ervonum;Combiquens;Femagest;Kombiquens;Megecat;Megeron;Megestat;Menoquens;Neo-delpregnin;Niaestine;Niagestine;Novaquin;Novokvens;Novolina;Novoquens;Oracolnal;Ovaban;Ovarid;Pallace;Serial 28;Volidan;Volplan.

World Health Organization (WHO)

Megestrol acetate, a synthetic progestogen, was introduced in the early 1960s as a component in oral contraceptive preparations. In 1967, as a result of new regulations required by the United States Food and Drug Administration, megestrol acetate was submitted to long-term toxicity studies and by the early 1970s it was shown to be associated with an increased incidence of mammary tumours in beagle bitches which led to its withdrawal by several regulatory authorities. Subsequently the validity of the beagle bitch model as a predictor of carcinogenicity of steroid contraceptives has been contested by many national regulatory authorities and megestrol remains available in some countries for contraceptive purposes. In other countries its use is restricted to anticancer treatment. (Reference: (WHODI) WHO Drug Information, 1-3, 5-7, 1984)

Synthesis

Megestrol, 17α-hydroxy-6α-methylpregna-4,6-dien-3,20-dione acetate (28.3.9), is a product of dehydrogenation medroxyprogesterone (28.3.7) with chloranil (tetrachloro-p-benzoquinone) in the presence of p-toluenesulfonic acid, which results in the formation of an additional double bond at position C6–C7, and subsequent acetylation of the product (28.3.8) leads to the desired megestrol (28.3.9) by acetic anhydride in the presence of p-toluenesulfonic acid.

Check Digit Verification of cas no

The CAS Registry Mumber 3562-63-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,5,6 and 2 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 3562-63:
(6*3)+(5*5)+(4*6)+(3*2)+(2*6)+(1*3)=88
88 % 10 = 8
So 3562-63-8 is a valid CAS Registry Number.
InChI:InChI=1/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18?,19?,20?,22?,23?,24-/m0/s1

3562-63-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name megestrol

1.2 Other means of identification

Product number -
Other names 17-Hydroxy-6-methyl-pregna-4,6-dien-3,20-dion

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:3562-63-8 SDS

3562-63-8Related news

Ten years of Croatian national guidelines for use of eicosapentaenoic acid and Megestrol (cas 3562-63-8) acetate in cancer cachexia syndrome – Evaluation of awareness and implementation among Croatian oncologists07/11/2019

SummaryBackground & aimsCancer cachexia (CC) syndrome and anorexia–cachexia syndrome are common terms used to describe changes in metabolism with increased inflammatory activity and can progressively develop through various stages such as pre-cachexia; cachexia; and refractory cachexia. Therefo...detailed

3562-63-8Relevant articles and documents

Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use

-

, (2008/06/13)

Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17β-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17β-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17β-hydroxysteroid dehydrogenase.

Novel 17-esters of 17α-hydroxy gestogens, compositions containing such compounds, processes for their preparation and methods of treatment therewith

-

, (2008/06/13)

This invention relates to novel 17α-esters of gestogens having an antitumour activity and to the preparation thereof. The invention is also concerned with pharmaceutical compositions containing the said compounds, and method of treatment therewith.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 3562-63-8